Type 1 Diabetes – January 2021 Type 1 Diabetes – January 2021 Adocia files patent for its innovative hydrogel scaffold cell therapy for the treatment of Type 1 Diabetes 11 Jan 2020 Hydrogel scaffold (β-cell therapy) – Adocia Adocia has […]
Type 1 Diabetes – January 2021 Type 1 Diabetes – January 2021 Tidepool completes FDA submission of Tidepool Loop an automated insulin dosing app for management of Type 1 Diabetes (T1D) 07 Jan 2021 Tidepool Loop (automated insulin dosing app) […]
Type 1 Diabetes – January 2021 Type 1 Diabetes – January 2021 REMD Biotherapeutics announced completion of enrollment and top-line results from Phase 2 trial of Volagidemab in patients with Type 1 Diabetes 07 Jan 2021 Volagidemab/ REMD-477 (Human IgG2 […]
Type 1 Diabetes – January 2021 Type 1 Diabetes – January 2021 Provention Bio announced U.S. FDA filing of a biologics license application (BLA) and priority review for Teplizumab for the delay or prevention of clinical Type 1 Diabetes in […]
Type 1 Diabetes – January 2021 Type 1 Diabetes – January 2021 Preclinical results in mice targeting transcriptional coregulator OCA-B/Pou2af1 and its effect on Type 1 Diabetes 09 Dec 2020 Objective: To assess if T cell-specific OCA-B deletion and pharmacologic […]
